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ovasc Surg. 2012;143:727-34.HeartWare ventricular assist device placement in a patient with
congenitally corrected transposition of the great arteriesJiapeng Huang, MD, PhD,a,b and Mark S. Slaughter, MD,c Louisville, KyCongenitally corrected transposition of the great arteries
(CC-TGA) is a rare anomaly that is seen in fewer than
0.5% of patients with clinically evident congenital heart
disease. Failure of the systemic ventricle (morphologi-
cally right ventricle [RV]) is the main cause of heart fail-
ure.1 Heart transplant is the treatment of choice for most
patients with CC-TGAwho are in end-stage heart failure.
Ventricular assist devices (VADs) may become necessary
to deal with progressive decline of end-organ function
during the wait for an appropriate donor. Patients with
CC-TGA present unique challenges for VAD implanta-
tion and management.
CLINICAL SUMMARY
A 66-year-old man with a diagnosis of CC-TGAwas seen
at an outside hospital for worsening shortness of breath. He
had shown slow progression to NewYork Heart Association
functional class IV symptoms during the previous 8 years.
His medical history was also significant for chronic atrial fi-
brillation and dyslipidemia. He was started on a continuous
milrinone infusion of 0.3 mg/(kg $ min) and transferred to
our hospital for possible VAD placement.
The patient’s preoperative hemodynamic values with
milrinone infusion were as follows: blood pressure,
110/65 mm Hg; heart rate, 90 beats/min; cardiac index,1.65 L/(min $ m2), and pulmonary vascular resistance,
129 dynes/(s $ cm5). After induction of general anesthesia,
transesophageal echocardiography (TEE) was performed.
The moderator band and the inferior insertion of the
atrioventricular valve leaflets helped to identify the left-
positioned ventricle as the morphologically RV and the
associated valve as the tricuspid valve. The tricuspid valve
was trileaflet, with a large prolapsed septal leaflet, a small
anterior leaflet, and a cleft posterior leaflet. The tricuspid
annulus was dilated to 49 mm, and color flowDoppler ultra-
sonography demonstrated severe tricuspid regurgitation.
The ejection fraction of the morphologically RV was only
20%, with RVend-diastolic diameter of 8.7 cm. The pulmo-
nary ventricle (morphologically left ventricle) function was
nearly normal, with an ejection fraction of 50%.
A standard sternotomywas performed. The systemic aorta
and right atrium were cannulated, and cardiopulmonary by-
passwas established.Because of concerns that themoderator
band andmultiple papillarymuscles in theRVmight obstruct
the VAD inflow cannula, an 18-gauge angiocatheter was in-
serted into the RV, and agitated saline solution was injected
to determine the optimal angle for the VAD inflow cannula.
When the tip of the angiocatheter was found to be in the mid
RV cavity without obvious obstruction, the sewing ring was
sutured and ventriculotomy was then performed with the
punch. On visual inspection, there were no significant cross-
ing fibers. A HeartWare HVAD (HeartWare, Inc, Miramar,
Fla) was then inserted with its center in the predetermined
site. The outflow cannula was then anastomosed to the sys-
temic aortawith a partially occluding aortic clamp. TEE ver-
ified that the VAD inflow cannula was positioned parallel to
the interventricular septum without significant obstruction.
Initially, a pump flow of 3.5 L/min was achieved after wean-
ing off cardiopulmonary bypass. The device was positioned
in the mediastinum, and the outflow graft was placed in the
pericardial well (Figures 1 and 2).
Postoperatively, the patient did well hemodynamically
and had good pump performance. On postoperative dayrdiovascular Surgery c Volume 145, Number 2 e23
FIGURE 1. Postoperative anteroposterior chest radiograph demonstrates
positioning of the HeartWare device leftward in the mediastinum.
Case Reports7, the patient was noted to have a sudden drop in the platelet
count and discoloration of his digits. The patient was
started on argatroban (GlaxoSmithKline, Philadelphia,
Pa) with the diagnosis of heparin-induced thrombocytope-
nia. He was treated for several weeks with argatroban and
was subsequently discharged to a rehabilitation facility.
Ultimately, he did require amputation of several digits. Af-
ter rehabilitation, the patient was discharged home with noFIGURE 2. Postoperative lateral chest radiograph demonstrates insertion
of the HeartWare inflow cannula posterior to the right ventricle.
e24 The Journal of Thoracic and Cardiovascular Surgfurther complications. Echocardiography 2 years after
VAD insertion showed mild tricuspid regurgitation. At
the time of this report, 24 months after VAD implantation,
the patient remains fully supported by his device and has
had no complications secondary to his congenital anatomic
variation.
DISCUSSION
CC-TGA refers to the abnormal looping pattern of
the heart tube during embryologic development which
results in discordance between the atrioventricular and ven-
triculoarterial connections. Only a minority of patients with
CC-TGA survive into their seventh or eighth decade, and
they are almost exclusively those who have no other associ-
ated anomalies.1 Our patient was fortunate not to have any
other anomalies other than a cleft tricuspid leaflet, which
helps explain the delayed onset of symptoms.
Failure of the systemic ventricle (morphologically RV) is
the norm and usually occurs earlier in life. Serial examina-
tions of the ejection fraction of the morphologically RVare
mandatory, along with careful evaluation of the tricuspid
valve morphology and competency. TEE offers superior im-
aging resolution and windows to delineate cardiac chamber
connections and associated anomalies.
Late referral for operative correction of CC-TGA is com-
mon among patients with a poor ejection fraction and is the
major predictive marker for poor survival after surgery.2
Options for our patient included heart transplant with
home inotropic support, VAD, or total artificial heart. His
worsening heart failure symptoms with milrinone infusion
made waiting for heart transplant unacceptable. With
a nearly normal pulmonary ventricle (morphologically
LV), we anticipated that a total artificial heart would not
be necessary and that a systemic VAD would be enough
to improve the patient’s function. Although about 10 pa-
tients have been reported in the literature with dextrotrans-
position of the great arteries and VAD support, only 3
cases have been reported of VAD placement in patients
with CC-TGA.3,4,5 HeartMate (Thoratec Corporation;
Pleasanton, Calif) VAD systems were used in 2 cases.
Because the systemic RV in CC-TGA lies posterior and in-
ferior to the LV (pulmonary ventricle), although it is less
posterior than a usual LV, this orientation might require un-
conventional positioning of VAD pumps. HeartMate VAD
pumps had to be placed close to the midline, which led to
abdominal wound dehiscence in 1 patient.3 Joyce and col-
leagues5 recently used the Debakey VAD (MicroMed Tech-
nology, Houston, Tex) in a patient with CC-TGA.5 They
resected significant amounts of RV trabeculae, rotated the
pump 180, and placed the pump in a more posterior posi-
tion to avoid inflow obstruction.
The HeartWare HVAD system is a small pump with
a wide-blade rotor design and a magnetically suspended im-
peller that generates centrifugal blood flow. This design hasery c February 2013
Case Reportsimproved durability and performance relative to previous
VADs. Our major rationale for choosing the HeartWare
HVAD was its relatively small size and ability to be con-
tained within the pericardium, thus eliminating the potential
need to create a pocket or rotate the pump configuration. In
addition, the device’s integrated inflow cannula could de-
crease the chance of inflow obstruction related to the abnor-
mal position of the ventricles in CC-TGA. TEE guidance
ensured successful selection of the optimal insertion site
for the VAD inflow cannula.
In summary, we report a case of successful HeartWare
HVAD implantation in a patient with CC-TGA to support
the function of the RV (systemic ventricle).From the Division of Cardiothoracic Surgery, Department of Surgery, Mayo Clinic
Arizona, Phoenix, Ariz.
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can be a fatal complication. Mechanical support to stabilize
the patient until repair or transplant may be necessary, be-
cause emergency operative repair carries a mortality as
high as 60%.1-3 The CardioWest Total Artificial Heart
(TAH-t; SynCardia Systems, Inc, Tucson, Ariz) has been
used successfully to replace the failing heart as a bridge
to transplant.4 We report the cases of the first 2 patients
treated with TAH-t implantation for unstable cardiogenic
shock resulting from post-MI VSD rupture.CLINICAL SUMMARIES
Patient 1
A68-year-oldmanwas transferred to our institution in ex-
tremis after an anterior MI and left anterior descending stent
2 placement weeks previously. Evaluation by echocardiog-
raphy showed a large pericardial effusion, a 22-mm apical
VSD, and biventricular failure. The patient had deterioration
to cardiogenic shock (systolic blood pressures less than 75mm Hg, pulmonary arterial pressure 50/20 mm Hg, central
venous pressure of 16-21 mm Hg, and pulmonary wedge
pressure of 31 mm Hg) and was intubated and transferred
to our institution on maximal pressor support. At arrival,
emergency venoarterial extracorporeal membrane oxygena-
tion (ECMO)was instituted through the femoral vessels, and
the patient’s condition was allowed to stabilize for 24 hours.
The patient underwent surgery for possible repair and device
support; however, because of extensive myocardial damage
and poor function, the decision was made intraoperatively
for TAH-t placement. The patient was extubated within 24
hours and supported for 76 days until heart transplant. He
had an uncomplicated hospital course and was discharged
2 weeks after transplant. At 3 years of follow-up, the patient
remains in excellent condition.Patient 2
A 65-year-old woman with a medical history significant
for diabetes mellitus type 2, hypertension, hyperlipidemia,
and sclerodermawas admitted to outside hospital for an acute
inferior MI. She was taken for emergency cardiac catheteri-
zation and had 2 stents placed in the proximal and mid right
dominant coronary artery. On the next day, she became dys-
pneic and hypotensive. Physical evaluation noted a newheart
murmur, and echocardiography revealed a large inferior base
VSDof 14mmwith biventricular failure. The patient was in-
tubated, an intra-aortic balloon pump was placed, and
pressor supportwasmaximized. The patient’s condition con-
tinued to deteriorate, and she was transferred to ourrdiovascular Surgery c Volume 145, Number 2 e25
